Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
NCT05682443Phase 2Active, not recruiting
- Sponsor
- OncoC4
- Start
- Dec 2023
- Primary completion
- Nov 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gotistobart in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by OncoC4. Primary endpoints: Dose-Limiting Toxicity at 40 months, Prostate-Specific Antigen 50% Decline at 40 months and 2 more. Started Dec 2023; status: active, not recruiting.
02
Drugs
gotistobart
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05682443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682443.